Physician profile
Till Peter Hansen
NPI 1720173214
$488,148.45
in general payments reported to CMS, 2019-2025
11 companies · $83K in 2025
The $83K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $63K · 2021: $71K · 2022: $91K · 2023: $51K · 2024: $76K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $191K · Travel and Lodging: $16K · Food and Beverage: $2,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $190,810.25 |
| Travel and Lodging | $15,604.95 |
| Food and Beverage | $2,949.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $214,237.08 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $206,864.85 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $47,669.84 | 2019-2022 | |
| Corcept Therapeutics | $15,317.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $3,161.95 | 2019 | |
| Amarin Pharma, INC. | $258.81 | 2019 | |
| Nxstage Medical, INC. | $175.05 | 2021 | |
| Radius Health, INC. | $144.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $77.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Till Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.